We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Genetic Mutations Linked to Rare Multiple Bowel Tumors

By LabMedica International staff writers
Posted on 28 Jul 2016
Most people with colorectal cancer will develop one primary tumor, which may then multiply and spread; however, in around 2% to 5% of colorectal cancer (CRC) cases, two primary tumors will originate and develop independently, known as synchronous colorectal cancer.

Genetic mutations have been identified that affect the immune system which may lead to the development of more than one bowel tumor at the same time and understanding how these cancers develop could improve targeting of therapies, but the causes of multiple tumors are still poorly understood.

A large team of scientists led by those at King's College London (UK) and the FIRC Institute of Molecular Oncology, (Milan, Italy) investigated whether the synchronous tumors had the same or different mutations and what genetic alterations could be predisposing people to develop more than one colorectal tumor. More...
They analyzed 20 synchronous colorectal cancers (syCRC) from 10 patients, and compared their genetics to people with only one colorectal cancer and to healthy people.

Tumors used in this study were collected from patients diagnosed with CRC who underwent surgical resection of two syCRC in a window of time of six months maximum. Five mononucleotides were analyzed by capillary gel electrophoresis and used as molecular markers of microsatellite instability in tumors of four patients. A tumor was classified as microsatellite unstable when at least one marker was found altered. Genomic DNA for all tumors, except one patient and seven matched normal tissues was extracted from 10 μm-thick formalin-fixed paraffin embedded (FFPE) sections using QIAamp DNA FFPE Tissue kit (Qiagen, Hilden, Germany). DNA from blood and frozen samples was also extracted. Libraries were sequenced using either HiSeq 2000 or HiSeq 2500 (Illumina, San Diego, CA, USA).

The genetic analysis found the synchronous tumors were not related to each other as they contained a variety of different genetic mutations that had led to cancer. This genetic variation makes synchronous colorectal cancers more difficult to treat, because therapies targeted at specific genetic aberrations in a person's cancer may not work if the other tumor has different genetic mutations. The team also found synchronous colorectal cancer patients had a higher occurrence of inherited damaging mutations in immune-related genes. Three-quarters of synchronous colorectal cancer patients were found to have rare damaging mutations in genes related to immune system function.

These patients had differences in the composition of their gut immune cells, which could lead to inflammation in the gut. The study authors conclude that synchronous colorectal cancer patients have inherited damaging alterations of immune-related genes, which may cause an inflammatory environment in the gut and increase the frequency of independent cancer-initiating events. The study was published on July 5, 2016, in the journal Nature Communications.

Related Links:
King's College London
FIRC Institute of Molecular Oncology
Qiagen
Illumina

Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Microbiology

view channel
Image: The model estimated about a fivefold return in gastric cancer prevention benefits per unit invested, with cost-effectiveness maintained in higher-cost settings (Image credit: Adobe Stock)

H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention

Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.